Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

EASD 2019 clinical trial overviews

EASD 2019 clinical trial overviews

GABA/GAD and type 1 diabetes progression

This trial looks at whether gamma aminobutyric acid, with or without glutamic acid decarboxylase, can slow the progression of newly diagnosed type 1 diabetes in children.

Tuesday, September 17, 12:00–13:00

The Beijing Community Diabetes Study

The investigators of this long-running study will present the 10-year cardiovascular and all-cause mortality outcomes.

Tuesday, September 17, 13:15–14:15

Teplizumab to delay type 1 diabetes onset

More details about the effects of teplizumab in people at high risk for type 1 diabetes will be forthcoming, following the initial positive results.

Tuesday, September 17, 13:15–14:15

The DECLARE-TIMI 58 trial

The DECLARE researchers will overview their cardiovascular and renal findings to date, and present subgroup analyses of the older study participants.

Wednesday, September 18, 12:00–13:00

The TIMES 1 trial

Investigators will give the first formal presentation of phase 3 data for the novel type 2 diabetes medication imeglimin.

Wednesday, September 18, 12:00–13:00

The DEFINE-HF trial

The DEFINE-HF team will report the effects of dapagliflozin in patients who have chronic heart failure with reduced systolic function.

Wednesday, September 18, 13:15–14:15

The VERIFY trial

VERIFY is testing first-line treatment of people with type 2 diabetes with vildagliptin plus metformin versus metformin alone.

Wednesday, September 18, 13:15–14:15

The RISE consortium

The investigators will present comparisons of the now complete individual RISE studies.

Thursday, September 19, 08:30–10:00

The CONCLUDE trial

This trial pits two long-acting insulins – degludec and glargine 300 – against each other in people with type 2 diabetes.

Thursday, September 19, 12:00–13:00

The REWIND trial

The REWIND investigators will present a subanalysis looking at the effect of dulaglutide on stroke risk in this relatively low-risk population of people with type 2 diabetes.

Thursday, September 19, 12:00–13:00

The PRIORITY trial

This trial will assess whether early intervention can slow progression of diabetic nephropathy and will test the ability of proteomics to predict progression.

Thursday, September 19, 13:15–14:15

The TEDDY study

Researchers for the ongoing TEDDY study will present data on the genetics and virus etiology of first-appearing autoimmunity.

Friday, September 20, 12:15–13:45